Article Details
Retrieved on: 2024-03-19 19:52:03
Tags for this article:
Click the tags to see associated articles and topics
Summary
AstraZeneca's acquisition of Fusion Pharmaceuticals for $2.4bn enhances its oncology portfolio with radioconjugates, a targeted cancer treatment, positioning it alongside competitors like Novartis in the pharmaceutical industry and leveraging business intelligence for strategic growth.
Article found on: www.pharmaceutical-technology.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here